Clik here to view.
Transgene和NEC启动两项AI驱动型抗癌疫苗TG4050治疗卵巢癌和头颈部癌的临床试验
法国斯特拉斯堡和东京 (美国商业资讯)–设计、开发基于病毒的免疫抗癌药的生物技术公司Transgene (Euronext Paris: TNG)和IT和网络技术领先者NEC Corporation (NEC; TOKYO:...
View ArticleClik here to view.
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial...
SHANGHAI & ST. HELIER, Jersey Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company...
View ArticleClik here to view.
三叶草生物制药在研1类新药SCB-313在中国开展的恶性胸水I期临床完成首例患者给药
成都 (美国商业资讯)–三叶草生物制药，一家全球临床阶段，致力于创新及变革性生物制药研发的生物制药公司，今天宣布在中国进行的又一个SCB-313 I期临床试验完成首例患者给药。SCB-313是一种创新重组人肿瘤坏死因子相关凋亡诱导配体（TRAIL）-...
View ArticleClik here to view.
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in...
CHENGDU, China Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was...
View ArticleClik here to view.
Inflazome IP Portfolio Strengthened with Patents Granted in US and Europe
DUBLIN & CAMBRIDGE, United Kingdom & BRISBANE, Australia Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple small molecule drugs that block harmful...
View ArticleClik here to view.
武田薬品：事業変革の進捗と優先事項の概要について第38回J.P. モルガン・ヘルスケア・カンファレンスにて発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 当社は、このたび、第38回J.P....
View ArticleClik here to view.
Takeda to Outline Progress on Business Transformation and Priorities at the...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) will provide an update on the progress of its business transformation and priorities today...
View ArticleClik here to view.
GeneMedicine Appoints MIT Professor Robert S. Langer, Sc.D to Its Scientific...
SEOUL, South Korea GeneMedicine Co., Ltd., a leader in the field of oncolytic adenovirus platform for the treatment of intractable cancers, announced today that the company has appointed Robert S....
View ArticleClik here to view.
Alpha Holdings Makes Superior, $39.3 Million Offer to OncoSec
SEONGNAM, South Korea Alpha Holdings, Inc. (KOSDAQ: 117670) (“Alpha”), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) (“OncoSec”), with an approximate 15.1% ownership stake,...
View ArticleClik here to view.
Lucence Presents Data Demonstrating Potential of AmpliMARK™-Powered...
MIAMI Singapore-based precision oncology startup Lucence, on the heels of its series A funding, is sharing early data highlighting the capabilities of its liquid biopsy technology to detect somatic...
View ArticleClik here to view.
武田将在第38届年度J.P.摩根健康产业大会上介绍业务转型和优先工作的进展情况
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502/NYSE:TAK)（以下称“武田”）将于今日在第38届年度J.P.摩根健康产业大会(J.P. Morgan Healthcare...
View ArticleClik here to view.
Alpha Holdings Sends Open Letter to OncoSec Stockholders Answering Questions...
SEONGNAM, South Korea Alpha Holdings, Inc. (KOSDAQ: 117670) (“Alpha”), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) (“OncoSec”), with an approximate 15.1% ownership stake,...
View ArticleClik here to view.
Cyclica and AUM Biosciences to Partner on Developing Novel Cancer Therapies...
TORONTO & SINGAPORE AUM Biosciences (AUM), a Singapore-headquartered clinical-stage biotechnology company committed to speedily developing affordable cancer therapies, and Cyclica, a...
View ArticleClik here to view.
INSERTING and REPLACING Alpha Holdings Sends Open Letter to OncoSec...
SEONGNAM, South Korea Insert new paragraph after the 1st paragraph under the “ADDITIONAL INFORMATION AND WHERE TO FIND IT“ section of the release. The corrected release reads: ALPHA HOLDINGS SENDS...
View ArticleClik here to view.
Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars...
SINGAPORE Mundipharma today announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong. The partnership covers Samsung...
View ArticleClik here to view.
MEVION S250i Selected by Jinshazhou Hospital to Equip New Proton Therapy...
LITTLETON, Mass. Mevion Medical Systems is pleased to announce it has signed an agreement for the sale of a MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning to Jinshazhou...
View ArticleClik here to view.
エメンド・バイオセラピューティクス、次世代のゲノム編集治療薬の開発推進に向け6100万ドルを調達
ニューヨーク （ビジネスワイヤ） — 合成生物学を活用して現時点で治療不可能な疾患に対処する次世代遺伝子編集のリーダー企業エメンド・バイオセラピューティクスは本日、日本を拠点とするバイオ製薬企業アンジェスが主導しての計6100万ドルのシリーズB資金調達について発表しました。本投資は、特定の適応症を対象とする開発でエメンドと提携することに対するアンジェスの戦略上の関心を反映したものです。...
View ArticleClik here to view.
ムンディファーマがサムスンバイオエピスと提携し、バイオシミラー製品を香港と台湾に拡大へ
シンガポール （ビジネスワイヤ） — ムンディファーマは本日、サムスンバイオエピス（Samsung Bioepis）と提携したと発表しました。台湾と香港でサムスンバイオエピスの初回分となるバイオシミラー候補の商業化に当たることが目的です。...
View ArticleClik here to view.
Mundipharma与Samsung Bioepis合作，将生物类似物拓展至香港和台湾
新加坡 (美国商业资讯)–Mundipharma今天宣布与Samsung Bioepis合作，在台湾和香港商业化Samsung Bioepis的首批生物类似物候选药物。 该合作覆盖Samsung Bioepis在免疫和肿瘤领域的生物类似物候选药物，包括SB5（阿达木单抗）、SB4（etanercept）、SB3（曲妥珠单抗）和SB8（贝伐单抗）。...
View ArticleClik here to view.
Alpha Holdings Comments on OncoSec’s Failure to Consider Superior Financing...
SEONGNAM, South Korea Alpha Holdings, Inc. (KOSDAQ: 117670) (“Alpha”), the largest stockholder of OncoSec Medical Incorporated (NASDAQ: ONCS) (“OncoSec”), with an approximate 15.1% ownership stake,...
View Article